Literature DB >> 25396301

Prevalence of asymptomatic vertebral fractures in late-onset Pompe disease.

Francesco Bertoldo1, Francesca Zappini, Martina Brigo, Maurizio Moggio, Valeria Lucchini, Corrado Angelini, Claudio Semplicini, Massimiliano Filosto, Sabrina Ravaglia, Sofia Cotelli, Alice Todeschini, Mauro Scarpelli, Serena Pancheri, Paola Tonin.   

Abstract

CONTEXT: Bone fragility and low bone mass have been reported in small case series of patients with Pompe disease with severely reduced muscle strength or immobilization.
OBJECTIVE: Our objective was to determine the prevalence of morphometric vertebral fractures and to evaluate bone mass in adults with late-onset Pompe disease.
DESIGN: We conducted a multicenter cross-sectional observational study from August 2012 to December 2013. STUDY
SETTING: All subjects were outpatients referred to University Referral Centers. PATIENTS: PATIENTS included 22 late-onset Pompe disease patients with progressive proximal myopathy and minimal respiratory involvement without other diseases affecting bone mass. MAIN OUTCOME MEASURE: The prevalence of morphometric vertebral fractures was systematically assessed by semiquantitative analysis of lateral spine x-rays (T4-L5).
RESULTS: A high prevalence of morphometric vertebral fractures was found. At least 1 vertebral fracture was present in 17 of 22 patients (77%). All vertebral fractures were asymptomatic. Bone mineral density was normal in 36.5% of the patients, whereas 36.5% were osteopenic and 27% were osteoporotic in at least 1 site. Fracture prevalence was independent of muscular and respiratory functional parameters and of genotype.
CONCLUSIONS: Our data show for the first time that asymptomatic and atraumatic vertebral fractures occur frequently in late-onset Pompe disease patients without a significant impairment of bone mass. Screening for asymptomatic vertebral fractures should be routinely performed in Pompe disease irrespective of the disease severity. Fracture risk should be confirmed in longitudinal studies.

Entities:  

Mesh:

Year:  2014        PMID: 25396301     DOI: 10.1210/jc.2014-2763

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Multisystem late onset Pompe disease (LOPD): an update on clinical aspects.

Authors:  Antonio Toscano; Carmelo Rodolico; Olimpia Musumeci
Journal:  Ann Transl Med       Date:  2019-07

2.  Non-osteogenic muscle hypertrophy in children with McArdle disease.

Authors:  I Rodríguez-Gómez; A Santalla; J Díez-Bermejo; D Munguía-Izquierdo; L M Alegre; G Nogales-Gadea; J Arenas; M A Martín; A Lucía; I Ara
Journal:  J Inherit Metab Dis       Date:  2018-03-28       Impact factor: 4.982

Review 3.  A Multidisciplinary Perspective Addressing the Diagnostic Challenges of Late-Onset Pompe Disease in the Arabian Peninsula Region Developed From an Expert Group Meeting.

Authors:  Ali Al Shehri; Abdullah Al-Asmi; Abdullah Mohammed Al Salti; Abubaker Almadani; Ali Hassan; Ahmed K Bamaga; Edward J Cupler; Jasem Al-Hashel; Majed M Alabdali; Mohammed H Alanazy; Suzan Noori
Journal:  J Neuromuscul Dis       Date:  2022

4.  Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD).

Authors:  Federica Montagnese; Francesca Granata; Olimpia Musumeci; Carmelo Rodolico; Stefania Mondello; Emanuele Barca; Maria Cucinotta; Anna Ciranni; Marcello Longo; Antonio Toscano
Journal:  J Inherit Metab Dis       Date:  2016-02-01       Impact factor: 4.982

5.  Improvement of bone mineral density after enzyme replacement therapy in Chinese late-onset Pompe disease patients.

Authors:  Bun Sheng; Yim Pui Chu; Wa Tai Wong; Eric Kin Cheong Yau; Sammy Pak Lam Chen; Wing Hang Luk
Journal:  BMC Res Notes       Date:  2017-07-28

Review 6.  Bone health in patients with inborn errors of metabolism.

Authors:  M Langeveld; C E M Hollak
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.